NCNA Quote, Financials, Valuation and Earnings

Bicycle Therapeutics Plc has a net margin of -- compared to NuCana Plc's net margin of -42.03%. NuCana Plc's return on equity of -215.21% beat Bicycle Therapeutics Plc's return on equity of -32.03%.

NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 1275973.62%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $12.67 which suggests that it could grow by 150.83%. Given that NuCana Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe NuCana Plc is more attractive than Bicycle Therapeutics Plc.

NuCana Plc has a beta of 1.791, which suggesting that the stock is 79.145% more volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.651, suggesting its more volatile than the S&P 500 by 65.123%.

NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend.

NuCana Plc quarterly revenues are --, which are smaller than Bicycle Therapeutics Plc quarterly revenues of $47.9M. NuCana Plc's net income of -$3.3M is higher than Bicycle Therapeutics Plc's net income of -$20.1M. Notably, NuCana Plc's price-to-earnings ratio is -- while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 4.98x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals Plc has a net margin of -- compared to NuCana Plc's net margin of --. NuCana Plc's return on equity of -215.21% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 1275973.62%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $7.02 which suggests that it could grow by 704.13%. Given that NuCana Plc has higher upside potential than Biodexa Pharmaceuticals Plc, analysts believe NuCana Plc is more attractive than Biodexa Pharmaceuticals Plc.

NuCana Plc has a beta of 1.791, which suggesting that the stock is 79.145% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.106, suggesting its more volatile than the S&P 500 by 10.59%.

NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.

NuCana Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. NuCana Plc's net income of -$3.3M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, NuCana Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -- compared to NuCana Plc's net margin of --. NuCana Plc's return on equity of -215.21% beat DBV Technologies SA's return on equity of -217.87%.

NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 1275973.62%. On the other hand DBV Technologies SA has an analysts' consensus of $39.89 which suggests that it could grow by 89.39%. Given that NuCana Plc has higher upside potential than DBV Technologies SA, analysts believe NuCana Plc is more attractive than DBV Technologies SA.

NuCana Plc has a beta of 1.791, which suggesting that the stock is 79.145% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.942, suggesting its less volatile than the S&P 500 by 194.186%.

NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

NuCana Plc quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. NuCana Plc's net income of -$3.3M is higher than DBV Technologies SA's net income of -$44.8M. Notably, NuCana Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Mereo BioPharma Group Plc has a net margin of -- compared to NuCana Plc's net margin of -2923.31%. NuCana Plc's return on equity of -215.21% beat Mereo BioPharma Group Plc's return on equity of -80.03%.

NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 1275973.62%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $1.75 which suggests that it could grow by 446.71%. Given that NuCana Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe NuCana Plc is more attractive than Mereo BioPharma Group Plc.

NuCana Plc has a beta of 1.791, which suggesting that the stock is 79.145% more volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.372, suggesting its less volatile than the S&P 500 by 62.788%.

NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.

NuCana Plc quarterly revenues are --, which are smaller than Mereo BioPharma Group Plc quarterly revenues of --. NuCana Plc's net income of -$3.3M is higher than Mereo BioPharma Group Plc's net income of -$7.3M. Notably, NuCana Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 97.45x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.